Home » Newsletters » BioWorld Science

BioWorld Science

April 10, 2012

View Archived Issues

New agent for liver disorders patented by Norgine Europe

First-in-class cancer immunotherapy well tolerated in phase I trial

Novel solute carrier family 22 member 12 inhibitors designed

Bristol-Myers Squibb presents novel HIV integrase inhibitors

Taiho Pharmaceutical reports new H-PGDS inhibitors

New protein kinase inhibitors disclosed by Bayer Schering Pharma

Cell-based gene therapy is well tolerated in phase I study

CSA-131 active against Gram-negative bacteria

ARMOR1 trial assesses safety of galeterone in prostate cancer

Amgen presents first preclinical data on novel anticancer drug

New data support potential of Cell-in-a-Box technology

Novel anticancer nanomedicine shows promise in clinical trial

DARPin-based VEGF inhibitor completes phase IIa trial

Muscular Dystrophy Association awards grant to Catabasis Pharmaceuticals

Sanofi and Alfresa Pharma launch vigabatrin collaboration

Stroke biomarker license granted to Randox

Spectrum Pharmaceuticals announces acquisition

Phase III results reported for apaziquone

Amorfix establishes proof of concept for lead tumor-specific antibody

FDA approves adjunct radioactive diagnostic for Alzheimer's disease

FDA advisory committee issues recommendation on Astellas' mirabegron

Preclinical studies demonstrate small molecule's efficacy to treat anterior uveitis

Phase I/II trial begins evaluating Syndax's entinostat with lapatinib in metastatic breast cancer

Winston Pharmaceuticals receives grant to develop civamide nasal solution

Pacira Pharmaceuticals launches Exparel in U.S.

Next-generation drug-eluting stent approved in Japan to treat coronary artery disease

Pharmos reports promising data from ongoing phase IIa trial of levotofisopam

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for June 17, 2025.
Zusduri flurry ends; ‘set up’ at ODAC, Urogen prevails with FDA
BioWorld
During a conference call after the U.S. FDA approval of Zusduri (mitomycin), Urogen Pharma Ltd. CEO Liz Barrett offered candid observations about a...
23andme founder-led group outbids Regeneron for company
BioWorld
The 23andme Holding Co.’s saga came full circle with founder Anne Wojcicki regaining control of the bankrupt genetic testing company in a bidding battle against...
Elevidys’ second liver death hits Sarepta, sends DMD ripples
BioWorld
How the U.S. FDA might respond became a serious question for Wall Street as Sarepta Therapeutics Inc. made known a second death due to acute liver failure with...